Paper Details

  1. Home
  2. Paper Details

[Tranylcypromine for chronic therapy-resistant agoraphobia with panic disorder and recurrent depressive disorder].

Author: BoernerReinhard J, LühringFrauke

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Tranylcypromine, a monoamine oxidase inhibitor (MAOI), was effective in treating therapy-resistant depression and agoraphobia in a patient who also received pharmacological, behavioral and psychodynamic interventions.
Paper Details　
Original Abstract of the Article :
Tranylcypromine has been recommend as an option for therapy-resistant depressive and anxiety disorders. In this case report the effectiveness of this medication as a part of a combined therapy-program including pharmacological, behavioural and psychodynamic interventions could be demonstrated on an ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0030-1248499

データ提供：米国国立医学図書館（NLM）

Tranylcypromine: A Beacon of Hope in the Treatment of Therapy-Resistant Agoraphobia

The study explores the effectiveness of [tranylcypromine] in treating [therapy-resistant agoraphobia with panic disorder and recurrent depressive disorder]. The authors present a case report highlighting the successful use of tranylcypromine as part of a comprehensive therapy program. This program includes various interventions, such as pharmacological, behavioral, and psychodynamic approaches. The researchers found that this combined strategy offered a promising solution for patients with therapy-resistant conditions, providing a beacon of hope in the face of seemingly insurmountable challenges.

Tranylcypromine: A New Path in the Treatment of Agoraphobia

The case report highlights the potential of tranylcypromine as a valuable addition to the treatment arsenal for therapy-resistant agoraphobia. This is akin to discovering a hidden oasis in the vast desert of treatment options, offering a new path to recovery for individuals who have previously encountered limited success.

A Multifaceted Approach to Treatment

The study emphasizes the importance of a comprehensive therapy program that combines various approaches to address the multifaceted nature of agoraphobia. This is similar to navigating a desert, where a successful journey requires a combination of tools and strategies, such as a compass, water, and local knowledge. By utilizing a multifaceted approach, clinicians can effectively address the various symptoms and underlying factors contributing to agoraphobia.

Dr.Camel's Conclusion

This case report demonstrates the potential of tranylcypromine as a valuable therapeutic option for therapy-resistant agoraphobia. The success of this combined therapy program underscores the importance of a comprehensive approach to treatment, utilizing various interventions to address the multifaceted nature of this complex condition.

Date :
  1. Date Completed 2011-02-28
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

20703987

DOI: Digital Object Identifier

10.1055/s-0030-1248499

Related Literature

Article Analysis
・Side Effects of tranylcypromine
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.